Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response

Putting the brakes on mammary tumorigenesis: Loss of STAT1 predisposes to intraepithelial neoplasias

(2015) Christine Schneckenleithner et al.   Oncotarget

Loss of STAT1 from Mouse Mammary Epithelium Results in an Increased Neu-Induced Tumor Burden

(2015) Peter J. Klover et al.   NEOPLASIA

CD69+CD4+CD25- T Cells, a New Subset of Regulatory T Cells, Suppress T Cell Proliferation through Membrane-Bound TGF- 1

(2014) Y. Han et al.   JOURNAL OF IMMUNOLOGY

STAT1 Signaling in CD8 T Cells Is Required for Their Clonal Expansion and Memory Formation Following Viral Infection In Vivo

(2014) M. Quigley et al.   JOURNAL OF IMMUNOLOGY

Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system

(2012) Metamia Ciampricotti et al.   NATURE MEDICINE

Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors

(2011) S. R. Mattarollo et al.   CANCER RESEARCH

Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation

(2011) Jennifer F. Raven et al.   CELL CYCLE

CXCR3 in T cell function

(2011) Joanna R. Groom et al.   EXPERIMENTAL CELL RESEARCH

Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification

(2011) J Tanizaki et al.   ONCOGENE

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy

(2011) J. Stagg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation

(2010) K. P. A. MacDonald et al.   BLOOD

The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity

(2010) SaeGwang Park et al.   CANCER CELL

Different Tumor Microenvironments Contain Functionally Distinct Subsets of Macrophages Derived from Ly6C(high) Monocytes

(2010) K. Movahedi et al.   CANCER RESEARCH

Myeloid-derived suppressor cell heterogeneity and subset definition

(2010) Elisa Peranzoni et al.   CURRENT OPINION IN IMMUNOLOGY

The dendritic cell–tumor cross-talk in cancer

(2010) Yuting Ma et al.   CURRENT OPINION IN IMMUNOLOGY

Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm

(2010) Subhra K Biswas et al.   NATURE IMMUNOLOGY

Trastuzumab Mediated T-Cell Response against HER-2/Neu Overexpressing Esophageal Adenocarcinoma Depends on Intact Antigen Processing Machinery

(2010) Francesca Milano et al.   PLoS One

HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment

(2009) Britta Weigelt et al.   BREAST CANCER RESEARCH AND TREATMENT

Myeloid-derived suppressor cells in mammary tumor progression in FVB Neu transgenic mice

(2009) Fuminori Abe et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies

(2009) J. Ozao-Choy et al.   CANCER RESEARCH

Gene modulation and immunoregulatory roles of Interferonγ

(2009) Banishree Saha et al.   CYTOKINE

Selective Response to InsulinVersusInsulin-Like Growth Factor-I and -II and Up-Regulation of Insulin Receptor Splice Variant B in the Differentiated Mouse Mammary Epithelium

(2009) Chiara Berlato et al.   ENDOCRINOLOGY

Precision-cut slice cultures of tumors from MMTV-neu mice for the study of the ex vivo response to cytokines and cytotoxic drugs

(2009) Nirmala Parajuli et al.   IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL

Therapeutic activity of sunitinib for Her2/neu induced mammary cancer in FVB mice

(2009) Fuminori Abe et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Infiltrating CD11b+CD11c+cells have the potential to mediate inducible nitric oxide synthase-dependent cell death in mammary carcinomas of HER-2/neu transgenic mice

(2009) Nirmala Parajuli et al.   INTERNATIONAL JOURNAL OF CANCER

Dendritic Cells Require STAT-1 Phosphorylated at Its Transactivating Domain for the Induction of Peptide-Specific CTL

(2009) A. Pilz et al.   JOURNAL OF IMMUNOLOGY

Signatures Associated with Rejection or Recurrence in HER-2/neu-Positive Mammary Tumors

(2008) A. Worschech et al.   CANCER RESEARCH

Natural Killer Cell Accumulation in Tumors Is Dependent on IFN-  and CXCR3 Ligands

(2008) M. Wendel et al.   CANCER RESEARCH